Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Development deals
Biotech
TScan’s strategy unaffected by Amgen scrapping $500M+ collab
“There are no planned changes to our wholly owned programs as a result of the Amgen collaboration being terminated,” TScan told Fierce.
Darren Incorvaia
Aug 19, 2026 5:31pm
Fierce Pharma
At ASCO, China biotech industry cements its coming of age
Jun 3, 2026 8:50am
AbbVie dips into boiling RAS waters with $1.45B biobucks deal
Apr 28, 2026 10:01am
Takeda tears up Denali partnership, returning dementia asset
Apr 6, 2026 1:50pm
Gilead garners lipid package for cancer asset in $300M pact
Jan 6, 2026 7:00am
VC Aditum launches new biotech for foray with Fosun
Dec 19, 2025 11:25am
